ClinicalTrials.gg
RecruitingNCT05824845Updated Nov 18, 2024

QIST Collaborative - Arthroplasty Research Cohort (ARC) Study

An observational study in Hip Arthritis and Knee Arthritis, sponsored by Northumbria Healthcare NHS Foundation Trust. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-18.

Sponsored by Northumbria Healthcare NHS Foundation Trust · Observational

How we know

From the registry’s dates

  • Started Jul 2023; still recruiting 3 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
5,000
Ages
18 Years and older
Sex
All
01

Study summary

The ARC Study is a national observational cohort study to investigate patient reported and clinical outcomes after hip and knee replacements. The study has the following objectives:

  1. To evaluate outcomes following hip and knee replacements.
  2. To determine risk factors for adverse outcomes in primary hip and knee replacements.
  3. To identify targets for future research and intervention in patients undergoing primary hip and knee replacements
  4. To provide a resource from which to identify potential participants for future clinical trials, and to use data collected in the ARC Study as comparison or control data for trial participants who have been randomised to receive one or more interventions.

Participants are recruited and consented online. Patients are invited to participate by collaborating surgical teams nationally in outpatient clinics at the time of being added to a waiting list, in addition to an advertising campaign to recruit patients. They are directed to an online portal where they will be able to review further information.

Consent and data collection is completed electronically through patients entering data online. Baseline demographics and characteristics are recorded, including details of socio-demographics, lifestyle, health status and patient reported outcome measures (PROMs). Patients then undergo hip/knee replacement and postoperative rehabilitation according to the standard care and protocols of the hospital and the preferences of their treating surgeon.

Follow-up data, including PROMs, is collected via online questionnaires up to two years following surgery. The study will ultimately also enable multiple trials to be embedded within the cohort study, using a 'Trials within Cohorts' (TwiCs) methodology.

02

Conditions studied

  • Hip Arthritis
  • Knee Arthritis

Keywords

  • Hip Replacement
  • Knee Replacement
03

In context

Lead sponsor

Northumbria Healthcare NHS Foundation Trust is the lead sponsor of 16 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

UK Residents age 18 years or over undergoing elective primary hip or knee replacement

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants must meet all of the inclusion criteria:

  1. UK Resident
  2. Able to read and understand documentation and questionnaires in English language
  3. Undergoing elective primary hip or knee arthroplasty (THR, TKR or UKR)
  4. Age 18 years or over
  5. Provides the necessary consents relating to data collection and use of study data, data linkage, future research and invitation to involvement in future trials

Exclusion criteria

Exclusion Criteria:

Provided a participant meets all of the inclusion criteria, there are no exclusion criteria for the cohort study.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
5,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • ARC Study Cohort

    Procedure: Hip/Knee Replacement

Interventions

  • ProcedureHip/Knee Replacement

    Hip/Knee Replacement

06

What researchers measure

Primary outcomes

  1. EQ-5D-5L health-related quality of life score

    Time frame: 2 years

Secondary outcomes

  1. PROMIS-10

    Patient-Reported Outcomes Measurement Information System Global Health

    Time frame: 2 years

  2. Oxford Hip Score

    Time frame: 2 years

  3. Oxford Knee Score

    Time frame: 2 years

  4. Musculoskeletal Health Questionnaire

    MSK-HQ

    Time frame: 2 years

  5. Hospital for Special Surgery Hip/Knee Replacement Expectations Surveys

    Perception of success/fulfilment of expectations

    Time frame: 2 years

  6. Patient Health Questionnaire-4

    PHQ-4

    Time frame: 2 years

  7. 11-point Numerical Pain Rating Scale

    Pain

    Time frame: 2 years

  8. Pain Catastrophising Scale

    Time frame: 2 years

  9. Length of stay

    Self-reported by study specific electronic questionnaire

    Time frame: 2 years

  10. Activity

    Levels of exercise and activity self-reported by study specific electronic questionnaire

    Time frame: 2 years

  11. Return to work

    Work status self-reported by electronic questionnaire using National Statistics Socio-economic Classification

    Time frame: 2 years

  12. Readmission within 30 days

    Time frame: 30 days

  13. Surgical Site Infection

    Time frame: 2 years

  14. Periprosthetic Fracture

    Time frame: 2 years

  15. Dislocation

    Time frame: 2 years

  16. Revision/Re-operation

    Time frame: 2 years

  17. Mortality

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2023 (actual). Primary completion is estimated for May 2030, 82 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2023
First posted
Apr 24, 2023
StartActual
Jul 13, 2023
Primary completionEst.
May 2030
CompletionEst.
May 2031
Last update
Nov 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05824845
Lead sponsor
Northumbria Healthcare NHS Foundation Trust
Collaborators
University of York
Responsible party
Sponsor
First posted
Apr 24, 2023
Start date
Jul 13, 2023
Primary completion
May 2030 (estimated)
Completion
May 2031 (estimated)
Last update
Nov 18, 2024

Study contacts

William Fishley
Contact
arcstudy@northumbria-healthcare.nhs.uk
01912934087

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion